The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
International Plasma Protein Congress Registration Now Open! +
IPPC 2015 REGISTRATION is now Open!!
10-11 March 2015
Preliminary program now available.Read More
Ebola Virus and Plasma Protein Therapies +
The recent outbreak of Ebola virus has caused great concern worldwide. We read stories about isolation, experimental therapies and many deaths. With the occurrence of the first transmissions of Ebola outside of West Africa, it becomes obvious that Ebola, as many other viruses originally confined to certain regions, can be introduced into other geographic areas through travelers who have visited countries where the virus is endemic.Read More
International Plasma Awareness Week to Celebrate Donors and Spotlight Rare Diseases +
Annapolis, MD--The second annual International Plasma Awareness Week (IPAW) will be celebrated October 12-18. A joint initiative of the Plasma Protein Therapeutics Association (PPTA) and its member companies, IPAW is designed to:Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly.
Read the current issue.